Section Arrow
Quote
CYCCP.NASDAQ
- Cyclacel Pharmaceuticals
Quotes are at least 15-min delayed:2025/03/28 05:29 EDT
Last
 --
-- (--)
Day High 
-- 
Prev. Close
5.44 
1-M High
16.9999 
Volume 
423 
Bid
--
Ask
--
Day Low
-- 
Open
-- 
1-M Low
4.84 
Market Cap 
1.82M 
Currency USD 
P/E -- 
%Yield 2.76 
10-SMA 5.97 
20-SMA 7.08 
50-SMA 7.23 
52-W High 19.4 
52-W Low 4.43 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
--/--
Enterprise Value
1.86M
Balance Sheet
Book Value Per Share
N/A
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
420.00K
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed：2025/03/28 05:29 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.